Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?
-
Published:2024-01
Issue:1
Volume:35
Page:10-14
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Giordano A.ORCID,
Lin N.U.,
Tolaney S.M.,
Mayer E.L.ORCID
Subject
Oncology,Hematology
Reference42 articles.
1. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro;Finn;Breast Cancer Res,2009
2. Cyclin D1 provides a link between development and oncogenesis in the retina and breast;Sicinski;Cell,1995
3. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer;Watt;Breast Cancer Res,2022
4. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020
5. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial;Johnston;Lancet Oncol,2023